Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $50 from $40 and keeps a Neutral rating on the shares. The firm also added an “upside 30-day catalyst watch” on the shares. Citi expects near-term approval of sepiapterin for phenylketonuria but continues to have measured longer term views on the drug’s peak sales potential.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- Cautious Outlook on PTC Therapeutics: Sepiapterin’s Limited Potential to Offset Declining DMD Revenues
- PTC Therapeutics Advances Long-Term Study on Vatiquinone for Friedreich Ataxia
- PTC Therapeutics’ Gene Therapy Trial: A Promising Update for Investors
- PTC Therapeutics Advances PKU Treatment with Sepiapterin Study
- PTC Therapeutics’ Vatiquinone Study: A Long-Term Commitment to Friedreich Ataxia